Worldwide Disease Industry to 2026 – by Diagnosis, Treatment and Region – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Graves Disease Market 2020-2026” report has been added to ResearchAndMarkets.com’s offering.

The global graves’ disease market is growing at a CAGR of 4.2% during the forecast period.

The growing prevalence of auto-immune disorders such as thyroid disorder has created the demand for its treatment which in turn is driving the graves’ disease market. Advancement in treatment technology for effective treatment of graves’ disease is one of the prime factors to drive the market growth. Further, the existence of favorable reimbursement policies, funding in the development of novel therapies among others are also estimated to drive the growth of the market. Reimbursement policies and practices reflect the considerable impact on the expansion of healthcare facilities, diagnosis services, and R&D activities. Reimbursement policies control the work of the research and development companies without any budget concerns and with better decisions and strategies. R&D of any drug and supporting policies go hand in hand. Better reimbursement policies draw significant spending on healthcare, particularly in research and development. Reimbursements offered by many governments and private insurance companies for Grave’s disease diagnosis and treatment are furthermore augmenting the growth of Grave’s disease market.

The higher inclination of the population towards a sedentary lifestyle is a significant cause of diseases related to the thyroid including hyperthyroidism, hypothyroidism, autoimmune diseases, goiter, and others. The growing trend of smoking, drinking alcohol, and unhealthy eating activity in emerging and developing countries due to sedentary lifestyles has to lead to severe auto-immune disorders.

The development of new technologies that have allowed ultrasound to become more widely adopted for soft tissue diagnosis across the globe is anticipated to offer lucrative opportunities for market growth during the forecast period. However, the high cost of treatment of Graves disorders and the unavailability of skilled medical professionals in developing and under-developed economies are certain factors that are hindering the growth of the market.

Market Players Outlook

Key players of the graves’ disease market include Rodos Biotarget GmbH, Sanofi Genzyme, Macleods Pharmaceuticals Ltd., Apitope International N.V., RLC Labs Inc. Takeda Pharmaceutical Co., Ltd., and Omeros Corp. To remain competitive in the market, these players adopt different marketing strategies such as product launches, mergers & acquisitions, and partnerships among others.

Recent Development

In July 2018, the German Federal Institute for Drugs and Medical Devices has given acceptance in 21 countries of the EU for a new formulation by Merck KGaA named Euthyrox (levothyroxine). Euthyrox is expected to have better control over individual levothyroxine dosage as the active ingredient is in the new formulation of Euthyrox enables patients.

In April 2018, Apitope Technology (Bristol) Ltd. announced the positive results of the phase I clinical trial of its product candidate ATX-GD-59 that is used for the treatment of Grave’s disease. This would allow the company to expand its market in Grave’s disease treatment. This strategy would help gain a significant market share in the future by having a ‘first-mover advantage’ unless a rival company launches a similar product.

The Report Covers

• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global graves disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where in the market.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights

3. Competitive Landscape

3.1. Key Company Analysis

3.1.1. Overview

3.1.2. Financial Analysis

3.1.3. SWOT Analysis

3.1.4. Recent Developments

3.2. Key Strategy Analysis

4. Market Determinants

4.1. Motivators

4.2. Restraints

4.3. Opportunities

5. Market Segmentation

5.1. GlobalGraves’ Disease market by Diagnosis

5.1.1. Ultrasound

5.1.2. Imaging Tests

5.1.3. Radioactive Iodine Uptake

5.1.4. Blood Sample

5.2. Global Graves’ Disease Market by Treatment

5.2.1. Anti- Thyroid Medication

5.2.2. Radioactive Iodine Therapy

5.2.3. Surgery

6. Regional Analysis

7. Company Profiles

7.1. AbbVie Inc.

7.2. Abbott Laboratories

7.3. Acella Pharmaceuticals, LLC

7.4. Allergan PLC

7.5. ApitopeInternational N.V.

7.6. AstraZeneca PLC

7.7. Bayer AG

7.8. Biomerieux S.A.

7.9. East West Pharma

7.10. EpiVax, Inc.

7.11. F.Hoffman-La-Roche AG

7.12. GlaxoSmithKline plc.

7.13. Lupin, Ltd.

7.14. Macleods Pharmaceuticals Ltd.

7.15. Merck KGaA

7.16. Mylan N.V.

7.17. Novartis International AG

7.18. Pfizer Inc.

7.19. RLC Labs

7.20. Sanofi S.A.

7.21. Takeda Pharmaceutical Co.Ltd.

7.22. Torrent Pharmaceuticals, Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/nfsltx

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900